Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/27245| Title: | An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia. | Authors: | Salvaris R.;Opat S. | Monash Health Department(s): | Haematology | Institution: | (Salvaris, Opat) Department of Haematology, Monash Health, 246 Clayton Rd, Clayton, VIC 3168, Australia (Salvaris) School of Clinical Sciences at Monash Health, Monash University, Wellington Rd, Clayton, VIC 3800, Australia | Issue Date: | 20-Feb-2021 | Copyright year: | 2021 | Publisher: | Future Medicine Ltd. | Place of publication: | United Kingdom | Publication information: | Future Oncology. 17 (4) (pp 371-387), 2021. Date of Publication: February 2021. | Journal: | Future Oncology | Abstract: | In the last decade, the treatment of chronic lymphocytic leukemia (CLL) has shifted away from chemoimmunotherapy toward targeted novel agents such as small molecule inhibitors and antibodies. Here, we give an overview of the pharmacology of venetoclax and obinutuzumab and the evidence from early phase to Phase III trials that have shaped how they are used in the treatment of CLL. Venetoclax, an oral anti-apoptotic BCL-2 inhibitor, in combination with a CD20 antibody has shown superiority to chemoimmunotherapy in treatment-naive and relapsed/refractory CLL. Obinutuzumab is a novel anti-CD20 monoclonal antibody that has been safely combined with novel agents including venetoclax and Bruton tyrosine kinase inhibitors and has shown superiority over rituximab when combined with chlorambucil.Copyright © 2020 Future Medicine Ltd. | DOI: | http://monash.idm.oclc.org/login?url= http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.2217/fon-2020-0640 |
PubMed URL: | 33064021 [http://www.ncbi.nlm.nih.gov/pubmed/?term=33064021] | ISSN: | 1479-6694 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/27245 | Type: | Article | Subjects: | drug safety drug tolerability dyspnea/si [Side Effect] febrile neutropenia/si [Side Effect] fever/si [Side Effect] human infection/si [Side Effect] infestation/si [Side Effect] infusion related reaction/dt [Drug Therapy] infusion related reaction/si [Side Effect] monotherapy nausea/si [Side Effect] neutropenia/si [Side Effect] pharmacodynamic parameters pharmacokinetic parameters pharmacological parameters phase 3 clinical trial (topic) pneumonia/si [Side Effect] priority journal pruritus/si [Side Effect] rigor/si [Side Effect] tachycardia/si [Side Effect] thrombocytopenia/si [Side Effect] tumor lysis syndrome/si [Side Effect] acalabrutinib/cb [Drug Combination] acalabrutinib/dt [Drug Therapy] bendamustine/dt [Drug Therapy] chlorambucil/ae [Adverse Drug Reaction] chlorambucil/cb [Drug Combination] chlorambucil/dt [Drug Therapy] clarithromycin/it [Drug Interaction] cyclophosphamide/cb [Drug Combination] cyclophosphamide/cm [Drug Comparison] cyclophosphamide/dt [Drug Therapy] fludarabine/cb [Drug Combination] fludarabine/cm [Drug Comparison] fludarabine/dt [Drug Therapy] hydrocortisone/dt [Drug Therapy] ibrutinib/cb [Drug Combination] ibrutinib/cm [Drug Comparison] ibrutinib/dt [Drug Therapy] *obinutuzumab/cb [Drug Combination] *obinutuzumab/dt [Drug Therapy] posaconazole/it [Drug Interaction] ritonavir/it [Drug Interaction] rituximab/ae [Adverse Drug Reaction] rituximab/cb [Drug Combination] rituximab/cm [Drug Comparison] rituximab/dt [Drug Therapy] *venetoclax/ae [Adverse Drug Reaction] *venetoclax/cb [Drug Combination] *venetoclax/cm [Drug Comparison] *venetoclax/it [Drug Interaction] *venetoclax/dt [Drug Therapy] *obinutuzumab/ae [Adverse Drug Reaction] abdominal pain/si [Side Effect] allogeneic hematopoietic stem cell transplantation anemia/si [Side Effect] article backache/si [Side Effect] cancer chemotherapy *cancer immunotherapy cancer recurrence *chronic lymphatic leukemia/dt [Drug Therapy] *chronic lymphatic leukemia/th [Therapy] diarrhea/si [Side Effect] drug efficacy drug metabolism drug potentiation drug potentiation drug safety drug tolerability dyspnea / side effect febrile neutropenia / side effect fever / side effect human infection / side effect infestation / side effect infusion related reaction / drug therapy / side effect monotherapy nausea / side effect neutropenia / side effect pharmacodynamic parameters pharmacokinetic parameters pharmacological parameters phase 3 clinical trial (topic) pneumonia / side effect priority journal pruritus / side effect rigor / side effect tachycardia / side effect Article tumor lysis syndrome / side effect anemia / side effect allogeneic hematopoietic stem cell transplantation abdominal pain / side effect thrombocytopenia / side effect backache / side effect cancer chemotherapy *cancer immunotherapy cancer recurrence *chronic lymphatic leukemia / *drug therapy / *therapy diarrhea / side effect drug efficacy drug metabolism |
| Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.